Cancer

Chris Williams, MD, PhD
April 8, 2024

Chris Williams named VICC director for Research Education

Chris Williams, MD, PhD, associate dean for Physician-Scientist Education and Training at Vanderbilt University, has been named to lead Research Education at Vanderbilt-Ingram Cancer Center.

By Tom Wilemon
Karen Winkfield, MD, PhD
April 8, 2024

Karen Winkfield named VICC director for Community Outreach and Engagement

Karen Winkfield, MD, PhD, Ingram Professor of Cancer Research, has been named associate director for Community Outreach and Engagement at Vanderbilt-Ingram Cancer Center.

By Tom Wilemon
Jennifer Pietenpol, PhD
April 5, 2024

Pietenpol to receive ASCO’s highest honor

Jennifer Pietenpol, PhD, will be recognized at the annual meeting of the American Society of Clinical Oncology (ASCO) with one of its highest honors.

By Tom Wilemon
Eunyoung Choi, PhD
April 5, 2024

Eunyoung Choi’s gastric cancer research merits AACR-Debbie’s Dream funding

Ongoing research by Eunyoung Choi, PhD, into how cells transform into abnormal versions of themselves that are the precursors to stomach cancer has received support from the American Association for Cancer Research.

By Tom Wilemon
March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

By Tom Wilemon
March 8, 2024

Scalp cooling allows woman to keep hair during chemotherapy

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.

By Tom Wilemon
March 5, 2024

GE HealthCare & Vanderbilt publish data on AI models predicting patient response to immunotherapy

The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center utilizing artificial intelligence to enable safer and more precise cancer immunotherapies show that the models they developed predict patient responses with 70% to 80% accuracy.
By Tom Wilemon
March 1, 2024

Study seeks to determine if fallopian tube sonograms can help detect ovarian cancer at early stage

Vanderbilt researchers are investigating whether sonograms of fallopian tubes can be effective for the early detection of ovarian cancer, and their ongoing study shows promise.
By Tom Wilemon
February 27, 2024

Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment

Multi-institutional study finds that enrollment and outcomes were similar across racial and ethnic groups for children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide.
By Leigh MacMillan
February 16, 2024

Waddell Walker Hancock Cancer Discovery Fund names first scholars

A research endeavor that seeks to develop a new cancer immunotherapy utilizing nanobody delivery and targeted heating of tumors has received funding from the Waddell Walker Hancock Cancer Discovery Fund.
By Tom Wilemon
February 7, 2024

Vanderbilt nanodrug may be a paradigm shift for cancer

A multidisciplinary research team at Vanderbilt University and Vanderbilt University Medical Center has discovered a new way to kill a tumor by disrupting its acidic “microenvironment” without harming normal tissue.
By Bill Snyder
January 31, 2024

Fatty acids rewire energy supply chain in stomach cancer development

A study by Vanderbilt researchers has revealed how metabolic changes spurred by fatty acids contribute to the transformation of cells into abnormal versions of themselves that are the precursors to stomach cancer.
By Tom Wilemon
January 24, 2024

Long-term follow-up pinpoints side effects of treatments for prostate cancer patients

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.
By Craig Boerner
1 … 3 4 5 6 7 … 69